Eli Lilly and Gilead Lead Pharma M&A Growth with Innovative Therapy Acquisitions, Including 'anito-cel'.
Eli Lilly's GLP-1 Obesity Drug-Driven M&A Spree
Eli Lilly (LLY) has generated substantial cash flow through its blockbuster obesity and diabetes drugs, Mounjaro and Zepbound. Leveraging this financial strength, Lilly has undertaken three major acquisitions in 2026, totaling $10.8 billion (USD) in upfront payments. A notable deal is the agreement to acquire Centessa Pharmaceuticals (CNTA), which holds cleminorexton, a Phase 2a narcolepsy and idiopathic hypersomnia treatment candidate, for a total of $7.8 billion. This demonstrates a strong commitment to securing next-generation core pipeline assets, even with limited patent cliff concerns.
Gilead's Strategy to Strengthen Cell Therapy Leadership
Gilead Sciences (GILD) has completed the acquisition of Arcellx (ACLX), its existing partner, for $7.8 billion (USD) to strengthen its position in the multiple myeloma cell therapy market. This acquisition grants Gilead full control over anitocabtagene autoleucel (anito-cel), a BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy candidate. With the FDA's Biologics License Application (BLA) review goal date (PDUFA date) set for December 23, 2026, the acquisition is believed to be a proactive move to eliminate existing royalty and milestone payment obligations. This reflects Gilead's astute financial decision to maximize profit margins upon successful commercialization.
Industry Pipeline Diversification Focused on Immunology and Neurology
In 2026, pharmaceutical M&A is diversifying beyond oncology into autoimmune diseases and the central nervous system (CNS). Biogen (BIIB) acquired Apellis (APLS), which holds SYFOVRE and EMPAVELI for geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), for $5.6 billion. UCB's acquisition of Candid Therapeutics for up to $2.2 billion to secure cizutamig, a Phase 2 dual antibody, follows a similar pattern. This strategic move aims to secure next-generation immune reset technology and capture a diversified market for various indications.
Market Restructuring and Valuation Increase Driven by Large Deals
The agreement for Sun Pharma, India's largest pharmaceutical company, to acquire Organon (OGN), a women's health and biosimilar specialist, for $11.75 billion (USD) marks the peak of the pharmaceutical M&A market this year. As large pharmaceutical companies invest heavily to overcome the patent cliff, the valuation of high-tech early-stage biotech companies is rapidly increasing. This influx of capital is promoting a positive industry cycle by significantly strengthening the infrastructure for clinical development and accelerating the progress of clinical trials. This will be an important opportunity to deliver innovative treatment options to patients more quickly.
Challenges in Regulatory Approval and Organizational Integration
While M&A activity is increasing, stricter antitrust reviews by regulatory bodies, including the Federal Trade Commission (FTC), are posing challenges for companies. Furthermore, early-stage pipeline assets, such as Eli Lilly's acquired narcolepsy treatment, cleminorexton, or Merck's (MRK) acquisition of Terns (TERN) to secure TERN-701, a chronic myelogenous leukemia (CML) treatment, carry development risks until final approval. Therefore, simply completing the acquisition is not enough; the success of M&A will depend on the smooth integration of the two organizations and the early realization of synergy effects.
The $23.5 billion in 2026 M&A deals led by Eli Lilly and Gilead clearly demonstrates the reinvestment of blockbuster GLP-1 obesity drug revenues and the competition to secure a leading position in the high-value multiple myeloma cell therapy market. In particular, 'anito-cel,' acquired by Gilead for $7.8 billion, is a key variable that will reshape the BCMA-targeted CAR-T market, currently dominated by BMS's Abecma and J&J's Carvykti, as it is in the BLA stage (PDUFA December 23, 2026). Lilly has also rapidly expanded its portfolio into the central nervous system (CNS) sleep disorder market, including narcolepsy, through the $7.8 billion acquisition of Centessa. In addition, large-scale deals, such as Biogen's acquisition of Apellis ($5.6 billion), are occurring simultaneously across the immunology and neurology markets, driving up the valuation of early-stage biotech companies. Investors and industry participants should closely analyze whether these large integration deals will translate into actual synergy creation and pass regulatory antitrust reviews to ultimately generate revenue.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/lilly-gilead-lead-pharmas-deal-merger-drug-acquisition/819676/